New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
16:20 EDTORCL, NGLS, ABBV, TRGP, DRI, SHPG, ETE, FLMLOn The Fly: Closing Wrap
Stocks on Wall Street had a quiet open and remained that way throughout the session. The averages moved in a narrow range but drifted mostly in positive territory, allowing the Dow and S&P 500 to close the week at all-time highs. The Nasdaq also notched a gain, despite being weighed on by shares of Oracle (ORCL), which slid after reporting earnings below Wall Street estimates. ECONOMIC EVENTS: In the U.S., no major economic data was reported. COMPANY NEWS: Shares of enterprise software provider Oracle sunk $1.69, or 3.98%, to $40.82 after the company’s fourth quarter results trailed analysts’ consensus estimates. Citigroup downgraded Oracle to Neutral from Buy citing weak license growth and "relatively aggressive" Q1 targets following the company's Q4 results... Shire (SHPG) shares trading in New York rose $31.18, or 16.26%, to $222.89 after the company confirmed it rejected a takeover offer from AbbVie (ABBV). Abbvie, which has tried unsuccessfully three times to strike a deal to buy the Ireland-based drugmaker, is considering raising its offer for Shire a fourth time, according to Bloomberg, citing two people with knowledge of the matter. MAJOR MOVERS: Among the notable gainers was car retailer CarMax (KMX), which surged $7.47, or 16.5%, to $52.75 after the company reported first quarter results that beat expectations. Also higher were shares of Flamel Technologies (FLML), which rose $2.40, or 18.79%, to $15.17 after the FDA changed its drug shortage website and now lists Flamel's Bloxiverz as the "first and only" approved neostigmine. Analysts at Summer Street believe the change could be a "hugely significant" milestone for Flamel and may mean that the FDA could be taking action to remove unapproved neostigmines offered by other companies. Among the noteworthy losers was Targa Resources Partners (NGLS), which fell $11.44, or 14.03%, to $70.11 after announcing last night that its takeover talks with Energy Transfer Equity (ETE) ended without a deal and the stock was downgraded at Wunderlich following the news. Shares of Targa Resources Partners and its parent, Targa Resources (TRGP), had spiked late in yesterday's session after Bloomberg reported that Energy Transfer was near a deal to buy them. Also lower was restaurant operator Darden (DRI), which dropped $1.94, or 3.92%, to $47.58 after stating that same-store sales at its Olive Garden restaurants had declined 3.5% last quarter and reporting earnings that disappointed. INDEXES: The Dow rose 25.62, or 0.15%, to 16,947.08, the Nasdaq advanced 8.71, or 0.2%, to 4,368.04, and the S&P 500 gained 3.39, or 0.17%, to 1,962.87.
News For ORCL;SHPG;ABBV;FLML;DRI;NGLS;ETE;TRGP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 15, 2014
08:41 EDTDRIDarden December volatility elevated into Q2 and outlook
Subscribe for More Information
08:16 EDTDRIDarden upgraded at Telsey Advisory
Subscribe for More Information
07:33 EDTORCLOracle upgraded at Morgan Stanley
As previously reported, Morgan Stanley upgraded Oracle to Overweight from Equal Weight. The firm's surveys indicate improving Cloud Apps growth in 2015 against low expectations and weak sentiment, favorable adoption of the new 12c database options next year, and improved perception value in Engineered Systems. Price target is $50.
06:34 EDTORCLOracle upgraded to Overweight from Equal Weight at Morgan Stanley
Subscribe for More Information
06:08 EDTDRIDarden upgraded to Market Perform from Underperform at Telsey Advisory
December 12, 2014
10:01 EDTORCLOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: BreitBurn Energy (BBEP) downgraded to Hold from Buy at Wunderlich... CIBC (CM) downgraded to Underperform from Neutral at Credit Suisse... Costco (COST) downgraded to Neutral from Buy at Janney Capital... Discovery (DISCA) downgraded to Sector Perform from Outperform at RBC Capital... Emerald Oil (EOX) downgraded to Neutral from Accumulate at Global Hunter... Goodrich Petroleum (GDP) cut to Underweight on lower oil at JPMorgan... Hain Celestial (HAIN) downgraded to Sector Perform from Outperform at RBC Capital... Hovnanian (HOV) downgraded to Neutral from Buy at Compass Point... Mindray Medical (MR) downgraded to Underweight from Equal Weight at Morgan Stanley... Morgan Stanley (MS) downgraded to Neutral from Buy at Buckingham... Oracle (ORCL) resumed with a Neutral from Overweight at Piper Jaffray... Rackspace (RAX) downgraded to Underperform from Neutral at DA Davidson... Zayo Group (ZAYO) downgraded to Neutral from Buy at BTIG.
07:24 EDTORCLOracle December volatility elevated into Q2 and outlook
Oracle December call option implied volatility is at 40, January is at 26, March is at 22; compared to its 26-week average of 22 according to Track Data suggesting larger near term price movement into the expected release of Q2 results after the close on December 17.
06:40 EDTORCLOracle resumed with a Neutral from Overweight at Piper Jaffray
Subscribe for More Information
December 11, 2014
10:13 EDTABBVOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARIAD (ARIA) downgraded at Credit Suisse... AbbVie (ABBV) downgraded to Equal Weight from Overweight at Morgan Stanley... Aimco (AIV) downgraded to Hold from Buy at KeyBanc... Anglo American (AAUKY) downgraded to Underperform from Neutral at Exane BNP Paribas... Approach Resources (AREX) downgraded at Sterne Agee... CommVault (CVLT) downgraded to Neutral from Outperform at Macquarie... Fifth Street Senior (FSFR) downgraded to Perform from Outperform at Oppenheimer... Harmonic (HLIT) downgraded to Neutral from Buy at Sidoti... Macerich (MAC) downgraded to Hold from Buy at Deutsche Bank... Newell Rubbermaid (NWL) downgraded to Outperform from Strong Buy at Raymond James... Olin Corp. (OLN) downgraded at Longbow... Penn West (PWE) downgraded to Underperform from Neutral at BofA/Merrill... Prudential plc (PUK) downgraded to Neutral from Buy at Nomura... Semiconductor Manufacturing (SMI) downgraded to Hold from Buy at Jefferies... Suncor (SU) downgraded to Neutral from Buy at BofA/Merrill... Talisman Energy (TLM) downgraded to Underperform from Neutral at BofA/Merrill... Thompson Creek (TC) downgraded to Hold from Buy at Deutsche Bank... Toll Brothers (TOL) downgraded to Underperform from Sector Perform at RBC Capital... Travelers (TRV) downgraded to Neutral from Buy at UBS... United Therapeutics (UTHR) downgraded at Credit Suisse... Vera Bradley (VRA) downgraded to Underperform from Neutral at Sterne Agee.
08:57 EDTSHPGLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
08:34 EDTABBVAbbVie downgraded at Morgan Stanley
Subscribe for More Information
07:54 EDTABBVGilead shares poised to continue to advance, says RBC Capital
Subscribe for More Information
06:29 EDTABBV, SHPGShire CEO sees no immediate need to spend break-up fee, Reuters reports
Subscribe for More Information
06:20 EDTABBVAbbVie downgraded to Equal Weight from Overweight at Morgan Stanley
December 10, 2014
10:27 EDTFLMLFlamel Technologies management to meet with Roth Capital
Subscribe for More Information
December 9, 2014
12:22 EDTSHPGPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:23 EDTSHPGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:44 EDTABBVAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:38 EDTSHPGShire downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
December 8, 2014
07:45 EDTFLMLFlamel Technologies price target raised to $29 from $21 at SunTrust
SunTrust increased its price target on Flamel after meeting with the company's CEO, as the firm now expects the company to raise the price of its Bloxiverz drug next year beyond the firm's previous outlook. SunTrust keeps a Buy rating on the shares.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use